Published in Eur J Nucl Med Mol Imaging on January 17, 2014
Tenascin-C: Exploitation and collateral damage in cancer management. Cell Adh Migr (2015) 0.85
New radiotracers for imaging of vascular targets in angiogenesis-related diseases. Adv Drug Deliv Rev (2014) 0.83
PET imaging of tenascin-C with a radiolabeled single-stranded DNA aptamer. J Nucl Med (2015) 0.81
A highly functional synthetic phage display library containing over 40 billion human antibody clones. PLoS One (2014) 0.80
Transcriptional regulation of tenascin genes. Cell Adh Migr (2015) 0.76
Can radioimmunotherapy promote from an orphan drug to daily clinical practice? Eur J Nucl Med Mol Imaging (2014) 0.75
Non-internalizing antibody-drug conjugates display potent anti-cancer activity upon proteolytic release of monomethyl auristatin E in the sub-endothelial extracellular matrix. Int J Cancer (2016) 0.75
Revised response criteria for malignant lymphoma. J Clin Oncol (2007) 22.19
OLINDA/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine. J Nucl Med (2005) 7.25
The role of angiogenesis in tumor growth. Semin Cancer Biol (1992) 5.33
Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival. J Clin Oncol (2008) 4.66
131I-tositumomab therapy as initial treatment for follicular lymphoma. N Engl J Med (2005) 3.38
MIRD pamphlet no. 16: Techniques for quantitative radiopharmaceutical biodistribution data acquisition and analysis for use in human radiation dose estimates. J Nucl Med (1999) 2.41
Molecular pathogenesis of Hodgkin's lymphoma: increasing evidence of the importance of the microenvironment. J Clin Oncol (2011) 1.94
Design and use of a phage display library. Human antibodies with subnanomolar affinity against a marker of angiogenesis eluted from a two-dimensional gel. J Biol Chem (1998) 1.83
Radioimmunotherapy of head and neck cancer xenografts using 131I-labeled antibody L19-SIP for selective targeting of tumor vasculature. J Nucl Med (2006) 1.62
The classical Hodgkin's lymphoma microenvironment and its role in promoting tumour growth and immune escape. J Pathol (2010) 1.55
(90)Yttrium-ibritumomab-tiuxetan as first-line treatment for follicular lymphoma: 30 months of follow-up data from an international multicenter phase II clinical trial. J Clin Oncol (2012) 1.50
A pilot study of rituximab in patients with recurrent, classic Hodgkin disease. Cancer (2003) 1.49
Design, construction, and characterization of a large synthetic human antibody phage display library. Proteomics (2005) 1.42
Bone marrow dosimetry for radioimmunotherapy: theoretical considerations. J Nucl Med (1993) 1.40
How I treat relapsed and refractory Hodgkin lymphoma. Blood (2011) 1.36
Tumor-targeting properties of novel antibodies specific to the large isoform of tenascin-C. Clin Cancer Res (2006) 1.23
Phase 2 study of rituximab plus ABVD in patients with newly diagnosed classical Hodgkin lymphoma. Blood (2012) 1.19
Novel treatment strategies for patients with relapsed classical Hodgkin lymphoma. Hematology Am Soc Hematol Educ Program (2009) 1.18
Expression of different tenascin isoforms in normal, hyperplastic and neoplastic human breast tissues. Int J Cancer (1992) 1.11
Absolute organ activity estimated by five different methods of background correction. J Nucl Med (1998) 1.06
Radioimmunotherapy of solid tumors by targeting extra domain B fibronectin: identification of the best-suited radioimmunoconjugate. Clin Cancer Res (2005) 0.99
Comparison of chemotherapy including escalated BEACOPP versus chemotherapy including ABVD for patients with early unfavourable or advanced stage Hodgkin lymphoma. Cochrane Database Syst Rev (2011) 0.94
Novel treatment strategies for patients with relapsed classical Hodgkin lymphoma. Blood Rev (2010) 0.90
Radioimmunotherapy in follicular lymphoma. Best Pract Res Clin Haematol (2011) 0.89
Inflammation and tissue repair markers distinguish the nodular sclerosis and mixed cellularity subtypes of classical Hodgkin's lymphoma. Br J Cancer (2009) 0.89
Managing relapsed and refractory Hodgkin lymphoma. Br J Haematol (2008) 0.88
Does rituximab have a place in treating classic hodgkin lymphoma? Curr Hematol Malig Rep (2010) 0.88
Radioimmunotherapy with radretumab in patients with relapsed hematologic malignancies. J Nucl Med (2012) 0.86
Tenascin in reactive lymph nodes and in malignant lymphomas. Pathol Res Pract (1992) 0.81
The expression of fibroblast growth factors and their receptors in Hodgkin's lymphoma. J Pathol (2006) 0.81
Phase 0 microdosing PET study using the human mini antibody F16SIP in head and neck cancer patients. J Nucl Med (2013) 0.80
Novel small-molecule therapy of Hodgkin lymphoma. Expert Rev Anticancer Ther (2007) 0.80
Comprehensive identification of proteins in Hodgkin lymphoma-derived Reed-Sternberg cells by LC-MS/MS. Lab Invest (2007) 0.80
Treatment of newly diagnosed advanced stage Hodgkin lymphoma. Blood Rev (2012) 0.78
Connective tissue growth factor is expressed in malignant cells of Hodgkin lymphoma but not in other mature B-cell lymphomas. Am J Clin Pathol (2010) 0.78
Influence of total-body mass on the scaling of S-factors for patient-specific, blood-based red-marrow dosimetry. Phys Med Biol (2007) 0.76
Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood (2006) 8.33
Survival after yttrium-90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona clinic liver cancer stages: a European evaluation. Hepatology (2011) 3.26
Gallstone ileus analysis of radiological findings in 27 patients. Eur J Radiol (2004) 2.52
The role of the EGFR signaling in tumor microenvironment. J Cell Physiol (2008) 2.34
Twenty years of radiobiology in clinical practice: the Italian contribution. Tumori (2015) 1.98
Comparison of the survival and tolerability of radioembolization in elderly vs. younger patients with unresectable hepatocellular carcinoma. J Hepatol (2013) 1.95
Brain white-matter volume loss and glucose hypometabolism precede the clinical symptoms of Huntington's disease. J Nucl Med (2006) 1.83
Gastro-duodenal perforations: conventional plain film, US and CT findings in 166 consecutive patients. Eur J Radiol (2004) 1.81
Immuno-inflammatory activation in acute cardio-embolic strokes in comparison with other subtypes of ischaemic stroke. Thromb Haemost (2009) 1.67
Enhancement of the antitumor properties of interleukin-2 by its targeted delivery to the tumor blood vessel extracellular matrix. Blood (2002) 1.66
A combined method for producing homogeneous glycoproteins with eukaryotic N-glycosylation. Nat Chem Biol (2010) 1.66
Rituximab and subcutaneous 2-chloro-2'-deoxyadenosine combination treatment for patients with Waldenstrom macroglobulinemia: clinical and biologic results of a phase II multicenter study. J Clin Oncol (2010) 1.63
Radioimmunotherapy of head and neck cancer xenografts using 131I-labeled antibody L19-SIP for selective targeting of tumor vasculature. J Nucl Med (2006) 1.62
Arterial stiffness indexes in acute ischemic stroke: relationship with stroke subtype. Atherosclerosis (2010) 1.61
Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinib. Blood (2013) 1.60
Three-dimensional reconstruction of tarantula myosin filaments suggests how phosphorylation may regulate myosin activity. J Mol Biol (2008) 1.59
Supraventricular tachycardias: proposal of a diagnostic algorithm for the narrow complex tachycardias. J Cardiol (2013) 1.58
18F-FDG PET is an early predictor of pathologic tumor response to preoperative radiochemotherapy in locally advanced rectal cancer. J Nucl Med (2006) 1.55
The classical Hodgkin's lymphoma microenvironment and its role in promoting tumour growth and immune escape. J Pathol (2010) 1.55
Inflammatory cytokines in acute ischemic stroke. Curr Pharm Des (2008) 1.54
Selective targeting of tumoral vasculature: comparison of different formats of an antibody (L19) to the ED-B domain of fibronectin. Int J Cancer (2002) 1.53
(90)Yttrium-ibritumomab-tiuxetan as first-line treatment for follicular lymphoma: 30 months of follow-up data from an international multicenter phase II clinical trial. J Clin Oncol (2012) 1.50
The immunocytokine L19-IL2 eradicates cancer when used in combination with CTLA-4 blockade or with L19-TNF. J Invest Dermatol (2012) 1.46
Fibronectin as target for tumor therapy. Int J Cancer (2006) 1.44
A precise stroke classification for evaluation of ischemic stroke subtypes and their relation with diabetes: is TOAST the best? Stroke (2010) 1.43
Complete eradication of human B-cell lymphoma xenografts using rituximab in combination with the immunocytokine L19-IL2. Blood (2008) 1.42
Association between low education and higher global cardiovascular risk. J Clin Hypertens (Greenwich) (2015) 1.42
Design, construction, and characterization of a large synthetic human antibody phage display library. Proteomics (2005) 1.42
Encoded self-assembling chemical libraries. Nat Biotechnol (2004) 1.40
A high-affinity human monoclonal antibody specific to the alternatively spliced EDA domain of fibronectin efficiently targets tumor neo-vasculature in vivo. Int J Cancer (2008) 1.36
In vivo protein biotinylation for identification of organ-specific antigens accessible from the vasculature. Nat Methods (2005) 1.32
Atherosclerosis as an inflammatory disease. Curr Pharm Des (2012) 1.31
Immunoscintigraphic detection of the ED-B domain of fibronectin, a marker of angiogenesis, in patients with cancer. Clin Cancer Res (2003) 1.31
Selective targeted delivery of TNFalpha to tumor blood vessels. Blood (2003) 1.29
Role of Spiral and Multislice Computed Tomography in the evaluation of traumatic and spontaneous oesophageal perforation. Our experience. Radiol Med (2005) 1.29
Non-Hodgkin's lymphoma and hepatitis C virus: a case-control study from northern and southern Italy. Int J Cancer (2004) 1.27
Antibody-radionuclide conjugates for cancer therapy: historical considerations and new trends. Clin Cancer Res (2011) 1.27
The extra-domain A of fibronectin is a vascular marker of solid tumors and metastases. Cancer Res (2007) 1.26
Tumor-targeting properties of novel antibodies specific to the large isoform of tenascin-C. Clin Cancer Res (2006) 1.23
Inflammation as a therapeutic target in acute ischemic stroke treatment. Curr Top Med Chem (2009) 1.21
Immunocytokines: a novel class of potent armed antibodies. Drug Discov Today (2012) 1.20
RD-CODOX-M/IVAC with rituximab and intrathecal liposomal cytarabine in adult Burkitt lymphoma and 'unclassifiable' highly aggressive B-cell lymphoma. Br J Haematol (2011) 1.20
High-throughput sequencing allows the identification of binding molecules isolated from DNA-encoded chemical libraries. Proc Natl Acad Sci U S A (2008) 1.18
Antibody-drug conjugates: basic concepts, examples and future perspectives. J Control Release (2012) 1.18
Photoinduced CO release, cellular uptake and cytotoxicity of a tris(pyrazolyl)methane (tpm) manganese tricarbonyl complex. Chem Commun (Camb) (2008) 1.17
The antibody-mediated targeted delivery of interleukin-15 and GM-CSF to the tumor neovasculature inhibits tumor growth and metastasis. Cancer Res (2007) 1.14
Modulation of gene expression by hypoxia in human umbilical cord vein endothelial cells: A transcriptomic and proteomic study. Proteomics (2004) 1.14
Inflammation in ischemic stroke subtypes. Curr Pharm Des (2012) 1.13
Arterial stiffness and ischemic stroke in subjects with and without metabolic syndrome. Atherosclerosis (2012) 1.12
Differentiation between high- and low-grade astrocytoma using a human recombinant antibody to the extra domain-B of fibronectin. Am J Pathol (2002) 1.12
Preclinical characterization of DEKAVIL (F8-IL10), a novel clinical-stage immunocytokine which inhibits the progression of collagen-induced arthritis. Arthritis Res Ther (2009) 1.12
In vivo imaging of inflammation- and tumor-induced lymph node lymphangiogenesis by immuno-positron emission tomography. Cancer Res (2010) 1.10
Isolation of high-affinity trypsin inhibitors from a DNA-encoded chemical library. Angew Chem Int Ed Engl (2007) 1.10
5-Aza-2'-deoxycytidine (decitabine) treatment of hematopoietic malignancies: a multimechanism therapeutic approach? Blood (2003) 1.10
Neoplastic leptomeningitis presenting in a melanoma patient treated with dabrafenib (a V600EBRAF inhibitor): a case report. J Med Case Rep (2012) 1.09
Accuracy of ultrasonography in the diagnosis of acute appendicitis in adult patients: review of the literature. Crit Ultrasound J (2013) 1.08
Purification of biotinylated proteins on streptavidin resin: a protocol for quantitative elution. Proteomics (2004) 1.08
Antibody-based targeting of the tumor vasculature. Biochim Biophys Acta (2007) 1.08
Neurological complications of Anderson-Fabry disease. Curr Pharm Des (2013) 1.06
Engineered vascular-targeting antibody-interferon-gamma fusion protein for cancer therapy. Int J Cancer (2005) 1.06
The tumour-targeting human L19-IL2 immunocytokine: preclinical safety studies, phase I clinical trial in patients with solid tumours and expansion into patients with advanced renal cell carcinoma. Eur J Cancer (2010) 1.05
Anderson-Fabry disease: a multiorgan disease. Curr Pharm Des (2013) 1.04
Expression of CCR5 receptors on Reed-Sternberg cells and Hodgkin lymphoma cell lines: involvement of CCL5/Rantes in tumor cell growth and microenvironmental interactions. Int J Cancer (2008) 1.04
Single nucleotide polymorphisms (SNPs) of pro-inflammatory/anti-inflammatory and thrombotic/fibrinolytic genes in patients with acute ischemic stroke in relation to TOAST subtype. Cytokine (2012) 1.04
High selenium intake and increased diabetes risk: experimental evidence for interplay between selenium and carbohydrate metabolism. J Clin Biochem Nutr (2010) 1.03
A chemical proteomics approach for the identification of accessible antigens expressed in human kidney cancer. Mol Cell Proteomics (2006) 1.03
Primary gastrointestinal stromal tumor of the liver with lung metastases successfully treated with STI-571 (imatinib mesylate). Front Biosci (2006) 1.03
Identification of new accessible tumor antigens in human colon cancer by ex vivo protein biotinylation and comparative mass spectrometry analysis. Int J Cancer (2008) 1.03
Diabetic and non-diabetic subjects with ischemic stroke: differences, subtype distribution and outcome. Nutr Metab Cardiovasc Dis (2007) 1.02
Neuron protection as a therapeutic target in acute ischemic stroke. Curr Top Med Chem (2009) 1.02
Body packing: a review of general background, clinical and imaging aspects. Radiol Med (2014) 1.02
Immunocytokines: a review of molecules in clinical development for cancer therapy. Clin Pharmacol (2013) 1.01
Antibody-mediated delivery of interleukin-2 to the stroma of breast cancer strongly enhances the potency of chemotherapy. Clin Cancer Res (2008) 1.01
DNA-encoded chemical libraries: advancing beyond conventional small-molecule libraries. Acc Chem Res (2014) 1.01
Synergistic therapeutic effects of a tumor targeting antibody fragment, fused to interleukin 12 and to tumor necrosis factor alpha. Cancer Res (2003) 1.01
A molecular model of phosphorylation-based activation and potentiation of tarantula muscle thick filaments. J Mol Biol (2011) 1.00
Molecular targeting of angiogenesis. Biochim Biophys Acta (2004) 1.00
Comparison of the binding and internalization properties of 12 DOTA-coupled and ¹¹¹In-labelled CCK2/gastrin receptor binding peptides: a collaborative project under COST Action BM0607. Eur J Nucl Med Mol Imaging (2011) 1.00
Rituximab therapy for chronic lymphocytic leukemia-associated autoimmune hemolytic anemia. Am J Hematol (2006) 1.00
Imaging of tumor angiogenesis using 99mTc-labeled human recombinant anti-ED-B fibronectin antibody fragments. J Nucl Med (2006) 1.00
In vivo targeting of tumor-associated carbonic anhydrases using acetazolamide derivatives. Bioorg Med Chem Lett (2009) 0.99
In vivo biotinylation of the vasculature in B-cell lymphoma identifies BST-2 as a target for antibody-based therapy. Blood (2009) 0.99
(124)I-L19-SIP for immuno-PET imaging of tumour vasculature and guidance of (131)I-L19-SIP radioimmunotherapy. Eur J Nucl Med Mol Imaging (2009) 0.99
20 years of DNA-encoded chemical libraries. Chem Commun (Camb) (2011) 0.99
Antibody-mediated delivery of IL-10 inhibits the progression of established collagen-induced arthritis. Arthritis Res Ther (2007) 0.99
Molecular imaging of atherosclerotic plaques using a human antibody against the extra-domain B of fibronectin. Circ Res (2004) 0.99
Early FDG PET response assessment of preoperative radiochemotherapy in locally advanced rectal cancer: correlation with long-term outcome. Eur J Nucl Med Mol Imaging (2012) 0.99
Human monoclonal antibodies to domain C of tenascin-C selectively target solid tumors in vivo. Protein Eng Des Sel (2006) 0.98
Different serum enzyme levels are required to rescue the various systemic features of the mucopolysaccharidoses. Hum Gene Ther (2010) 0.98